Design peptide-MHC (pMHC) therapeutic candidates targeting wheat, dairy, and soy allergens for eosinophilic esophagitis (EoE) treatment using GPU-accelerated molecular design.

This session aimed to design peptide-MHC (pMHC) therapeutic candidates targeting wheat, dairy, and soy allergens as a treatment approach for eosinophilic esophagitis (EoE), using GPU-accelerated molecular design.

The agent produced pMHC structural models for the three target allergens (wheat, dairy, soy), compiled these into a broader therapeutic bundle, and generated supporting manuscript, business, and presentation materials (including a peer-reviewed integrated business/scientific report and a program website). In this particular session, the agent revised that integrated report and website (v5 and v2 respectively) to correct three factual issues flagged by review: clarifying a discrepancy between 151 Program B hits and 33 dual-program hits, adding a caveat that the perturb-seq data underlying an "n=5 EoE patients" claim was actually from healthy donors and required EoE-patient validation as a Phase 1 gate, and adding the missing Phase 4 cost estimate ($80–140k) to the website's phase-by-phase budget itemization (bringing the total to $275–457k across five phases).

The corrected deliverables from this session are EoE_FINAL_INTEGRATED_BUSINESS_SCIENTIFIC_REPORT.md (v5) and eoe_program_website_deployment.zip (v2). These sit within a larger 65-artifact project set that includes pMHC structure files (wheat_pmhc.pdb, dairy_pmhc.pdb, soy_pmhc.pdb, dairy_singlechain.pdb), manuscript drafts (e.g., EoE_Final_Manuscript_Main.docx), figures illustrating the design strategy and nanoparticle architecture, and a biotech pitch deck (EoE_pMHC_Biotech_Pitch_Deck.pptx).